Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation
This study is currently recruiting participants.
Verified January 2012 by Grupo Espanol de trasplantes hematopoyeticos y terapia celular
Sponsor:
Grupo Espanol de trasplantes hematopoyeticos y terapia celular
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
Grupo Espanol de trasplantes hematopoyeticos y terapia celular
ClinicalTrials.gov Identifier:
NCT01455051
First received: October 17, 2011
Last updated: January 10, 2012
Last verified: January 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is currently recruiting participants. |
|---|---|
| Estimated Study Completion Date: | October 2017 |
| Estimated Primary Completion Date: | October 2014 (Final data collection date for primary outcome measure) |